Drug Profile
Pralatrexate - Acrotech Biopharma
Alternative Names: 10-Propargyl-10-deazaaminopterin; Difolta; FOLOTYN; Folotyn; PDXLatest Information Update: 22 Feb 2024
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center; Southern Research Institute; SRI International
- Developer Acrotech Biopharma; Columbia University; Mundipharma International; Rafa Laboratories; Servier
- Class Antineoplastics; Pterins; Small molecules
- Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Peripheral T-cell lymphoma
- Phase I/II Lymphoma; Multiple myeloma
- No development reported B-cell lymphoma; Bladder cancer; Breast cancer; Cutaneous T-cell lymphoma; Hodgkin's disease; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
Most Recent Events
- 16 Feb 2024 Launched for Peripheral T-cell lymphoma (Second-line therapy or greater) in China (IV)
- 27 Nov 2023 Phase-III clinical trials in Peripheral T-cell lymphoma (Combination therapy, First-line therapy) in USA (IV)
- 12 Oct 2023 Acrotech Biopharma plans a phase III CRESCENDO trial for Peripheral T-cell lymphoma (Combination therapy) in USA in October 2023 (Parenteral) (NCT06072131)